Lipid Nanoparticle Manufacturing With Controlled Mixing for Consistent Potency

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for preparing lipid nanoparticles (LNPs) used in delivering nucleic acids are variable in size and encapsulation efficiency due to difficulties in controlling formulation parameters, leading to inconsistent potency and increased adverse reactions in vaccines like mRNA COVID-19 vaccines.

Innovation Solution

A method involving precise control of mixing ratios and pH adjustment during the preparation of lipid nanoparticles, using specific lipid and nucleic acid concentrations, to enhance the potency and encapsulation efficiency of LNPs.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If current methods for preparing lipid nanoparticles are used, then production can be achieved, but the size and encapsulation efficiency are variable leading to inconsistent potency

Engineering Contradiction:

ImproveLNP size and encapsulation efficiencyVSAvoidformulation parameters control

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by optimizing specific formulation parameters including lipid to nucleic acid ratios (N:P ratio between 2:1 to 10:1), pH adjustment to physiological range (7.0-7.4), and precise control of mixing conditions. These parameter optimizations directly improve LNP size uniformity and encapsulation efficiency while resolving the contradiction between manufacturing precision and formulation complexity.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent implements feedback control through real-time monitoring and adjustment of formulation parameters during the LNP preparation process. By measuring actual LNP characteristics and adjusting formulation conditions accordingly, the method achieves consistent potency and encapsulation efficiency, addressing the variability issue while providing a systematic approach to parameter control.

Inventive Principle:

Principle #23Feedback

2Reliability

If higher concentrations of biologically active agents are used to overcome delivery restrictions, then cellular uptake may improve, but toxic effects and side effects increase

Engineering Contradiction:

Improvedelivery efficiencyVSAvoidtoxic effects and side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the physical and chemical parameters of the delivery system by optimizing LNP composition (specific lipid formulations with N:P ratios), size distribution (narrow polydispersity index), and surface properties (physiological pH). These parameter changes enable efficient cellular uptake at lower concentrations of biologically active agents, thereby improving delivery reliability while reducing toxic effects and side effects.

Inventive Principle:

Principle #35Parameter changes

3Manufacturing precision

If viral vectors are used to transfer genes, then gene introduction efficiency improves, but the ability to introduce chemically synthesized molecules is lost

Engineering Contradiction:

Improvegene introduction efficiencyVSAvoidability to introduce chemically synthesized molecules

Core Design Contradiction:

Manufacturing precisionVSAdaptability or versatility

Solution Approach 1:

The patent creates a universal lipid nanoparticle delivery system that can accommodate multiple types of nucleic acid payloads including chemically synthesized molecules (siRNA, antisense oligonucleotides), viral vectors, and other biologically active agents. The standardized LNP formulation with optimized composition and physiological pH provides multi-functional capability, resolving the contradiction between delivery efficiency and versatility.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method results in LNPs with enhanced potency, improved encapsulation efficiency, and reduced adverse reactions, making them suitable for large-scale vaccine production and global distribution.

Implementation Method 1

An alternative approach is to use delivery compositions incorporating cationic lipids, which interact with a biologically active agent at one part and interact with a membrane system at another part.

Methodology Applied

Scientific EffectElectrostatic interactions: Electrostatics

Implementation Method 2

adjusting the pH in the mixing solution to physiological pH to obtain a pH-adjusted mixing solution

Methodology Applied

Scientific EffectpH adjustment:

Data Source

PatentUS12458604B2Methods of lipid nanoparticle manufacture and compositions derived therefrom

Publication Date: 2025.11.04 THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

AI summary

Disclosed herein are methods of increasing the potency of nucleic acid loaded lipid nanoparticles (naLNPs) through certain novel and surprisingly superior LNP manufacturing techniques. Also disclosed are pharmaceutical compositions containing naLNPs manufactured according to the manufacturing methods described herein. The methods disclosed herein overcome major technical difficulties and high costs associated with previous LNP manufacturing techniques. The methods disclosed herein, therefore, greatly improve the industrial production of LNPs in unexpected ways thereby providing more potent naLNPs for nucleic acid delivery. Specifically, the invention disclosed herein are methods that show increased potency naLNPs due to increased mixing concentration of the lipids and mRNA during assembly.